Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions

Keyphrases

• Scientific Sessions 100%
• Homozygous Familial Hypercholesterolemia (HoFH) 100%
• Cardiovascular Prevention 100%
• Prevention Studies 100%
• Lipoproteins 66%
• Small Interfering RNA (siRNA) 33%
• High Risk 33%
• Physical Activity 33%
• MiRNA Target 33%
• Innovative Strategies 33%
• Type 2 Diabetic Patients 33%
• Acute Pancreatitis 33%
• Coaching 33%
• Acute Coronary Syndrome 33%
• Cardiovascular Outcomes 33%
• Coronary Artery Bypass Graft Surgery 33%
• Statin Therapy 33%
• Lipid-lowering Therapy 33%
• Overweight or Obesity 33%
• Disrupter 33%
• Decision Support System 33%
• Third Generation 33%
• Heart Failure with Preserved Ejection Fraction (HFpEF) 33%
• Cardiovascular Risk Management 33%
• Intracoronary 33%
• Transcriptomic Signature 33%
• Chylomicronemia 33%
• Semaglutide 33%
• PCSK9 Inhibitors 33%
• App-based 33%
• SELECT Trial 33%
• Evolocumab 33%
• Intensive Blood Pressure Control 33%
• Coronary Plaque Characteristics 33%

Medicine and Dentistry

• Familial Hypercholesterolemia 100%
• Lipoprotein 100%
• Cardiovascular Disease Prevention 100%
• Blood Pressure 50%
• Cardiovascular System 50%
• Pressure Control 50%
• Physical Activity 50%
• Small Interfering RNA 50%
• Disease Management 50%
• Transcriptomics 50%
• Patient with Type 2 Diabetes 50%
• Acute Pancreatitis 50%
• Coronary Artery Bypass Surgery 50%
• Statin 50%
• Chylomicronemia 50%
• Patient History of Coronary Artery Bypass Graft 50%
• Semaglutide 50%
• Acute Coronary Syndrome 50%
• Evolocumab 50%
• Obicetrapib 50%
• Oral 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Familial Hypercholesterolemia 100%
• Lipoprotein A 100%
• Cardiovascular Disease 100%
• Syndrome 50%
• Small Interfering RNA 50%
• Acute Pancreatitis 50%
• Statin (Protein) 50%
• Acute Coronary Syndrome 50%
• Patient History of Coronary Artery Bypass Graft 50%
• Semaglutide 50%
• Obicetrapib 50%
• Evolocumab 50%
• Maturity Onset Diabetes of the Young 50%